Drugs and toxins-associated pulmonary arterial hypertension: Lessons learned and challenges ahead

International Journal of Clinical Practice

Volumn 65, Issue SUPPL. 169, 2011, Pages 8-10

  De Jesus Perez, V ^a   Kudelko, K ^a   Snook, S ^a   Zamanian, R T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; ANOREXINOGEN; COCAINE; DEXFENFLURAMINE; FENFLURAMINE; ILLICIT DRUG; METHAMPHETAMINE; PHENTERMINE; TOXIN; UNCLASSIFIED DRUG; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT;

CASE CONTROL STUDY; CONFERENCE PAPER; DRUG EXPOSURE; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; LUNG PARENCHYMA; OBESITY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SUBSTANCE ABUSE; URINALYSIS; CHEMICALLY INDUCED DISORDER; HUMAN; IDIOPATHIC PULMONARY HYPERTENSION; REVIEW;

AMPHETAMINES; APPETITE DEPRESSANTS; COCAINE; HUMANS; HYPERTENSION, PULMONARY;

EID: 78650835061     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02606.x     Document Type: Conference Paper

References (14)

1. Fishman AP,. Aminorex to fen/phen: an epidemic foretold. Circulation 1999; 99: 156 - 61.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573 - 619.
3. Greiser E,. Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. Internist (Berl) 1973; 14: 437 - 42.
4. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609 - 16.
5. Rich S, Rubin L, Walker AM, et al. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000; 117: 870 - 4.
6. Walker AM, Langleben D, Korelitz JJ, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J 2006; 152: 521 - 6.
7. Wolff AJ, O'Donnell AE,. Pulmonary effects of illicit drug use. Clin Chest Med 2004; 25: 203 - 16.
8. Bailey ME, Fraire AE, Greenberg SD, et al. Pulmonary histopathology in cocaine abusers. Hum Pathol 1994; 25: 203 - 7.
9. Collazos J, Martinez E, Fernandez A, et al. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996; 90: 171 - 4.
10. Albertson TE, Walby WF, Derlet RW,. Stimulant-induced pulmonary toxicity. Chest 1995; 108: 1140 - 9.
11. Winslow BT, Voorhees KI, Pehl KA,. Methamphetamine abuse. Am Fam Physician 2007; 76: 1169 - 74.
12. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993; 104: 614 - 6.
13. Chin KM, Channick RN, Rubin LJ,. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130: 1657 - 63.
14. Snook S, Kudelko K, Spiekerkoetter E, et al. Characterization of patients with drugs and toxins associated pulmonary arterial hypertension: a clinical and outcomes perspective. J Heart Lung Transplant 2009; 28: S110.